Recent research conducted jointly by the University of Twente and Rousselot has highlighted a crucial, often overlooked factor in improving the reliability of 3D in vitro tumor models: the presence of endotoxins. These large, immunogenic molecules, commonly found in the environment, can significantly affect the reliability of results. Elevated levels of endotoxins can potentially lead to misinterpretation of the safety and efficacy of novel therapeutic approaches.
The study examines how endotoxins affect communication between macrophages and cancer cells and highlights the importance of using purified biomaterials, such as Rousselot's X-Pure gelatin methacrylate (GelMA), to ensure accurate research results.
TO HIGHLIGHT THIS RECENT RESEARCH, THE SEPTEMBER ISSUE OF EUROPEAN PHARMACEUTICAL REVIEW FEATURES INSIGHTS FROM DR. CATARINA FERREIRA DA SILVA, ROUSSELOT'S SCIENCE INTEGRATION MANAGER.
DR. CATARINA FERREIRA DA SILVA.
click here to read the September issue of EUROPEAN PHARMACEUTICAL REVIEW
Advancing biomedical research through purified biomaterials
In the quest to advance biomedical research, purified biomaterials have emerged as a crucial component in the development of novel therapeutics and medical devices. They play a key role in improving the reliability of in vitro 3D tumor models, particularly in cancer research, offering new ways to test the efficacy of immunotherapies without the need for animal testing. As the demand for purified biomaterials continues to grow, Rousselot's commitment to consistency and purity ensures that researchers have access to the highest quality resources for their innovative applications.
The versatility of gelatin in biomedical research
Gelatin's unique ability to mimic the natural composition and mechanical properties required by various cell types makes it an indispensable and versatile resource in the biomedical field. Its applications range from the development of organ-on-a-chip systems to tissue engineering, implants and wound healing. Rousselot's team of experts combines cutting-edge technology with 130 years of gelatin and collagen experience to offer tailormade solutions, enabling our customers to replicate in vivo conditions and harness the potential of 3D cell culture
Improve patient safety and product efficacy with X-Pure
Regulatory bodies, such as the European Medicines Agency (EMA) and the Food and Drug Administration (FDA), impose stringent requirements to ensure patient safety and product efficacy. Rousselot's X-Pure range of highly purified gelatins have been meticulously formulated to support compliance with global regulatory requirements. By choosing purified biomaterials from the start of research, our customers can reduce the likelihood of encountering compliance hurdles down the line, ultimately speeding up the route to market.
Purified biomaterials support drug development
By significantly reducing the cost, time, and ethical concerns associated with animal testing, purified biomaterials such as X-Pure are paving the way for accelerated delivery of new and improved immunotherapies to patients. They also improve the reliability of preclinical testing, ultimately ensuring that breakthrough therapies reach their intended recipients more quickly.